A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease - RAGNI, M. V.; JANKOWITZ, R. C.; CHAPMAN, H. L.; MERRICKS, E. P.; KLOOS, M. T.; DILLOW, A. M.; NICHOLS, T. C. (Haemophilia : the official journal of the World Federation of Hemophilia, 2008)
Keywords: Adult; Deamino Arginine Vasopressin - adverse effects; Deamino Arginine Vasopressin - therapeutic use; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor VIII - metabolism; Female; Hemostatics - adverse effects; Hemostatics - therapeutic use; Humans; Injections, Subcutaneous; Interleukin-11 - administration & dosage; Interleukin-11 - adverse effects; Interleukin-11 - therapeutic use; Male; Platelet Count; Polymerase Chain Reaction - methods; Prospective Studies; recombinant interleukin-11; Recombinant Proteins - therapeutic use; RNA, Messenger - genetics; von Willebrand disease; von Willebrand Diseases - blood; von Willebrand Diseases - drug therapy; von Willebrand factor; von Willebrand Factor - biosynthesis; von Willebrand Factor - genetics; von Willebrand Factor - metabolism; Young Adult